Antibody may improve treatment response in lung cancer
Researchers at UT Southwestern have identified an experimental antibody that targets the PCDH7 protein to shrink non-small cell lung cancer tumors. This treatment shows promise for patients who have developed resistance to existing KRAS inhibitor therapies.
Why it matters
This discovery offers a potential new therapeutic pathway for the most common form of lung cancer, addressing a critical gap in treatment for drug-resistant cases.
Kathryn O’Donnell, Ph.D., is Associate Professor of Molecular Biology and a member of the Harold C. Simmons Comprehensive Cancer Center at UT Southwestern.
The report is a straightforward summary of scientific research findings published in a peer-reviewed journal.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in